Bonnell Brian Michael
Known title: Chief Financial OfficerCIK: 0001804831
Associated companies
Transaction History
| ICUI | ▼ Sell | Open Market | 6,381 | $1.1M | 9/1/2026 | View on chart |
| ICUI | ▼ Sell | Open Market | 1,712 | $293K | 8/31/2026 | View on chart |
| ICUI | ▼ Sell | Open Market | 1,914 | $329K | 8/31/2026 | View on chart |
| ICUI | ▼ Sell | Open Market | 4,568 | $792K | 8/31/2026 | View on chart |
| ICUI | ▼ Sell | Open Market | 1,113 | $194K | 8/31/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 11,400 | $0 | 3/15/2026 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 5,800 | $730K | 3/15/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 3,248 | $0 | 3/15/2026 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,795 | $226K | 3/15/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 71,757 | $0 | 3/8/2026 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 39,667 | $5.2M | 3/8/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 3,522 | $0 | 3/7/2026 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,263 | $0 | 3/7/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 3,248 | $0 | 3/15/2025 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 2,146 | $0 | 3/7/2025 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 3,247 | $0 | 3/15/2024 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,780 | $175K | 3/15/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 2,210 | $0 | 3/8/2024 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,212 | $127K | 3/8/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 7,289 | $0 | 3/8/2024 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 3,998 | $418K | 3/8/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 2,145 | $0 | 3/7/2024 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,175 | $124K | 3/7/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 12,872 | $0 | 3/7/2024 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 7,059 | $744K | 3/7/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 2,209 | $0 | 3/8/2023 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,163 | $182K | 3/8/2023 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 2,145 | $0 | 3/7/2023 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,129 | $178K | 3/7/2023 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,551 | $0 | 3/6/2023 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 816 | $132K | 3/6/2023 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 8,745 | $0 | 3/6/2023 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 4,604 | $742K | 3/6/2023 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 2,209 | $0 | 3/8/2022 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 1,163 | $0 | 3/8/2022 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 722 | $0 | 3/6/2022 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 380 | $92K | 3/6/2022 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,551 | $0 | 3/6/2022 | View on chart |
| ICUI | ▼ Sell | Tax Withholding | 816 | $198K | 3/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ICU Medical Highlighted in Zacks Industry Outlook
ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.
ICU Medical Highlighted in Zacks Industry Outlook. ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.